Last updated: 2026-10-13 23:40:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Immunome, Inc. (IMNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.57, with a market capitalisation of $2.31B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.53 to $30.06. This page covers its latest market performance, valuation, price trends and company information.
$2.31B | |
$19.06 | |
$63.78 | |
$2.09 | |
$19.15 | |
1.88M | |
1.19M | |
-- | |
$30.06 | |
$13.53 | |
-- | |
-- |
Immunome, Inc. (IMNM) is trading at $17.68 in after-hours trading as of 2026-10-13 23:31:00, down 7.66% ($1.47) from the regular-session close of $19.15.
After-hours trading shows how investors are pricing IMNM after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Immunome, Inc. (IMNM) moved from $20.90 to $17.57, representing a decline of 15.95% ($3.33).
The stock traded between $17.43 and $21.48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.40 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 24.4%
IMNM is currently trading at $17.57, placing it 24.4% of the way from its 52-week low of $13.53 to its 52-week high of $30.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 177 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunome, Inc. (IMNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.